A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

What Was Tested

In this phase 3 trial, researchers set out to test Mazdutide.

It had three arms (groups): Placebo (placebo comparator), IBI362-dose2 (experimental) and IBI362-dose1 (experimental).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 180 planned participants were the target.

It was open to people of any sex aged from 12 years up to 18 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female participants aged ≥12 years and \<18 years at the time of signing the informed consent/assent form. Weight change \<5 kg after ≥12 weeks of diet and exercise alone before screening (per self/parental report).

The full record lists 3 inclusion and 3 exclusion criteria; among the exclusions: prior diagnosis of type 1 diabetes; pre-pubertal participants (tanner stage i); history of (or planned) bariatric surgery (except liposuction/abdominoplasty or acupuncture for weight loss performed \>1 year before screening).

How the Study Was Run

Design: randomized, sequential and double-blind.

Random assignment meant chance, not the researchers, decided who got Mazdutide and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Mazdutide.

Those kept unaware of assignments: participant and investigator.

It started in 2025-12-29 with completion listed for 2027-10-31.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percent Change from Baseline in BMI (time frame: Week 32).

It also tracked 3 secondary outcomes, for example Percent Change from Baseline in BMI.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Mazdutide in 180 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Mazdutide compound page, all human trials.